Case Studies

Symeres: Advancing sustainable drug discovery and development

By October 22, 2025No Comments

Case Study

Symeres: Advancing sustainable drug discovery and development

Headquartered in Europe, Symeres is a leading Contract Research Organization (CRO) specializing in integrated drug discovery and development services. With over 600 scientists and state-of-the-art facilities, the company provides end-to-end solutions from hit finding to clinical drug substance API manufacturing.

”Sustainability in pharmaceutical R&D is a strategic priority that enhances efficiency, compliance, and long-term resilience. At Symeres, we integrate sustainable practices into drug discovery and development to optimize resource use, improve process efficiency, and meet industry standards. This approach strengthens our operations and delivers value to our partners,
patients, and stakeholders while aligning with evolving regulatory expectations.

Jorg BenningshofHead of Scientific Operations at Symeres

Symeres ESG Pillars

Environment

  • Carbon footprint
  • Minimizing waste
  • Efficient use of water and resources

Social

  • Health and safety
  • Employee well-being
  • Contributing to local communities

Governance

  • Transparency
  • Risk management
  • Ethical business practices

Aligned with:

Sustainability at Symeres:
A strategic approach

Symeres integrates sustainability across six key pillars:

  • Innovation and sustainable chemistry:
    Leveraging green chemistry principles to reduce waste, improve process efficiency, and develop more sustainable synthesis routes.

  • Energy efficiency and resource optimization:
    Implementing strategies to lower energy consumption across research and production facilities.

  • Responsible supply chain:
    Collaborating with suppliers to ensure ethical sourcing of materials and promote responsible procurement.

  • Workforce well-being and inclusion:
    Investing in a diverse and inclusive workplace, promoting employee safety, mental well-being, and continuous learning.

  • Ethical business practices:
    Maintaining strict regulatory compliance, integrity, and corporate responsibility throughout all operations.

  • Community and scientific engagement:
    Supporting educational initiatives, partnering with biotech innovators, and driving forward sustainable pharmaceutical development.

Sustainable impact in action

600
+
scientists driving sustainable drug development

Dedicated ESG Task Force monitoring sustainability progress

50
%
reduction in scope 1 & 2 emissions by 2030
> 90
%
of employees engaged in learning & development programs
25
+
research & junior scientist internships offered annually

Discover more case studies

View all

3PBiovian: Strategic approach to workforce excellenceCase Studies

3PBiovian: Strategic approach to workforce excellence

3PBiovian is a leading pan-European biologicsContract Development and ManufacturingOrganization.
Onventis: Transforming procurement with sustainable innovationCase Studies

Onventis: Transforming procurement with sustainable innovation

Onventis is a leading provider of cloud-based procurement solutions, empowering businesses to digitalize their entire…
CatSci: Driving sustainable innovationCase Studies

CatSci: Driving sustainable innovation

Headquartered in the United Kingdom, CatSci Ltd is an award-winning innovation partner for medicines development,…
INKE’s strategic response to resource efficiencyCase Studies

INKE’s strategic response to resource efficiency

INKE is a leading global manufacturer of inhalation active pharmaceutical ingredients (APIs), established in 1980…
ESG in Focus: Valiantys’ sustainability vision and impactCase Studies

ESG in Focus: Valiantys’ sustainability vision and impact

Since 2022, Keensight has been an investor in Valiantys, a global leader in enterprise DevOps…